177Lu-PSMA-617在晚期前列腺癌和脑转移患者中的活性

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-01-31 DOI:10.1016/j.clgc.2025.102309

Narmeen S. Rashid , Avina Rami , Min Lang , Hailey Stoltenberg , Andrew Wolanski , Jolivette Ritzer , Heather Jacene , Praful Ravi

{"title":"177Lu-PSMA-617在晚期前列腺癌和脑转移患者中的活性","authors":"Narmeen S. Rashid , Avina Rami , Min Lang , Hailey Stoltenberg , Andrew Wolanski , Jolivette Ritzer , Heather Jacene , Praful Ravi","doi":"10.1016/j.clgc.2025.102309","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>While 177Lu-PSMA-617 (LuPSMA) is a proven life-prolonging therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), little is known about its efficacy in patients with central nervous system (CNS) metastasis.</div></span></li><li><span>•</span><span><div>In this case series, some CRPC patients with CNS disease had a partial or mixed intracranial response to LuPSMA, typically combined with brain-directed therapy, but others developed new brain metastasis or experienced neurological decline.</div></span></li><li><span>•</span><span><div>Though LuPSMA appears to have some intracranial activity, a multimodal approach with adjunctive use of local therapy is likely needed for patients with CNS disease.</div></span></li></ul></div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 2","pages":"Article 102309"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases\",\"authors\":\"Narmeen S. Rashid , Avina Rami , Min Lang , Hailey Stoltenberg , Andrew Wolanski , Jolivette Ritzer , Heather Jacene , Praful Ravi\",\"doi\":\"10.1016/j.clgc.2025.102309\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><ul><li><span>•</span><span><div>While 177Lu-PSMA-617 (LuPSMA) is a proven life-prolonging therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), little is known about its efficacy in patients with central nervous system (CNS) metastasis.</div></span></li><li><span>•</span><span><div>In this case series, some CRPC patients with CNS disease had a partial or mixed intracranial response to LuPSMA, typically combined with brain-directed therapy, but others developed new brain metastasis or experienced neurological decline.</div></span></li><li><span>•</span><span><div>Though LuPSMA appears to have some intracranial activity, a multimodal approach with adjunctive use of local therapy is likely needed for patients with CNS disease.</div></span></li></ul></div></div>\",\"PeriodicalId\":10380,\"journal\":{\"name\":\"Clinical genitourinary cancer\",\"volume\":\"23 2\",\"pages\":\"Article 102309\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical genitourinary cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1558767325000114\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767325000114","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

-虽然177Lu-PSMA-617（LuPSMA）已被证实是一种可延长转移性抗性前列腺癌（mCRPC）患者生命的疗法，但人们对它在中枢神经系统（CNS）转移患者中的疗效却知之甚少。-在这个病例系列中，一些患有中枢神经系统疾病的CRPC患者对LuPSMA（通常与脑引导疗法相结合）产生了部分或混合的颅内反应，但其他患者则出现了新的脑转移或神经功能衰退。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases

•
While 177Lu-PSMA-617 (LuPSMA) is a proven life-prolonging therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), little is known about its efficacy in patients with central nervous system (CNS) metastasis.
•
In this case series, some CRPC patients with CNS disease had a partial or mixed intracranial response to LuPSMA, typically combined with brain-directed therapy, but others developed new brain metastasis or experienced neurological decline.
•
Though LuPSMA appears to have some intracranial activity, a multimodal approach with adjunctive use of local therapy is likely needed for patients with CNS disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.